Camille L. Bedrosian
CIK: 0001326969
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (18 total)
- Sep 10, 2026AMLX
Amylyx Pharmaceuticals, Inc.
Sale(S)Direct7.9K shares at avg. $32.21$256K - Sep 10, 2026AMLX
Amylyx Pharmaceuticals, Inc.
Sale(S)Direct2.1K shares at avg. $33.09$69K - Sep 1, 2026CRNX
Crinetics Pharmaceuticals, Inc.
Disposition(D)Direct5.9K shares at avg. $85.00$504K - Sep 1, 2026CRNX
Crinetics Pharmaceuticals, Inc.
Disposition(D)Direct16.3K shares at avg. $85.00$1.4M - Aug 18, 2026AMLX
Amylyx Pharmaceuticals, Inc.
Award(A)Direct22.8K shares- - Jun 18, 2026CRNX
Crinetics Pharmaceuticals, Inc.
Award(A)Direct5.9K shares- - Mar 5, 2026AMLX
Amylyx Pharmaceuticals, Inc.
Award(A)Direct96K shares- - Mar 2, 2026AMLX
Amylyx Pharmaceuticals, Inc.
Sale(S)Direct6.5K shares at avg. $14.58$94K - Dec 1, 2025AMLX
Amylyx Pharmaceuticals, Inc.
Sale(S)Direct6.6K shares at avg. $14.35$94K - Sep 30, 2025AMLX
Amylyx Pharmaceuticals, Inc.
Sale(S)Direct12K shares at avg. $14.58$176K - Jun 24, 2025RYTM
RHYTHM PHARMACEUTICALS, INC.
Award(A)DirectRestricted Stock Units
4.7K shares- - Jun 24, 2025RYTM
RHYTHM PHARMACEUTICALS, INC.
Award(A)DirectStock Option (right to buy)
7K shares- - Jun 18, 2025RYTM
RHYTHM PHARMACEUTICALS, INC.
Exercise(M)Direct4K shares- - Jun 11, 2025CRNX
Crinetics Pharmaceuticals, Inc.
Award(A)Direct6.9K shares- - Mar 31, 2025AMLX
Amylyx Pharmaceuticals, Inc.
Sale(S)Direct12.4K shares at avg. $3.47$43K - Mar 6, 2025AMLX
Amylyx Pharmaceuticals, Inc.
Award(A)Direct68.4K shares- - Dec 2, 2024AMLX
Amylyx Pharmaceuticals, Inc.
Sale(S)Direct5.4K shares at avg. $5.54$30K - Sep 30, 2024AMLX
Amylyx Pharmaceuticals, Inc.
Sale(S)Direct11.4K shares at avg. $3.20$37K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 10, 2026 |  AMLX Amylyx Pharmaceuticals, Inc. | Sale(S) | 7,947 | $32.21 | $256,004 | Direct |
| Sep 10, 2026 | AMLX Amylyx Pharmaceuticals, Inc. | Sale(S) | 2,081 | $33.09 | $68,864 | Direct |
| Sep 1, 2026 |  CRNX Crinetics Pharmaceuticals, Inc. | Disposition(D) | 5,925 | $85.00 | $503,625 | Direct |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Disposition(D) | 16,300 | $85.00 | $1,385,500 | Direct |
| Aug 18, 2026 | AMLX Amylyx Pharmaceuticals, Inc. | Award(A) | 22,807 | - | $0 | Direct |
| Jun 18, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Award(A) | 5,925 | - | $0 | Direct |
| Mar 5, 2026 | AMLX Amylyx Pharmaceuticals, Inc. | Award(A) | 95,990 | - | $0 | Direct |
| Mar 2, 2026 | AMLX Amylyx Pharmaceuticals, Inc. | Sale(S) | 6,461 | $14.58 | $94,205 | Direct |
| Dec 1, 2025 | AMLX Amylyx Pharmaceuticals, Inc. | Sale(S) | 6,580 | $14.35 | $94,418 | Direct |
| Sep 30, 2025 | AMLX Amylyx Pharmaceuticals, Inc. | Sale(S) | 12,039 | $14.58 | $175,518 | Direct |
| Jun 24, 2025 |  RYTM RHYTHM PHARMACEUTICALS, INC. | Award(A) Restricted Stock Units | 4,712 | - | - | Direct |
| Jun 24, 2025 | RYTM RHYTHM PHARMACEUTICALS, INC. | Award(A) Stock Option (right to buy) | 7,037 | - | - | Direct |
| Jun 18, 2025 | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise(M) | 4,000 | - | - | Direct |
| Jun 11, 2025 | CRNX Crinetics Pharmaceuticals, Inc. | Award(A) | 6,900 | - | - | Direct |
| Mar 31, 2025 | AMLX Amylyx Pharmaceuticals, Inc. | Sale(S) | 12,425 | $3.47 | $43,082 | Direct |
| Mar 6, 2025 | AMLX Amylyx Pharmaceuticals, Inc. | Award(A) | 68,420 | - | - | Direct |
| Dec 2, 2024 | AMLX Amylyx Pharmaceuticals, Inc. | Sale(S) | 5,421 | $5.54 | $30,007 | Direct |
| Sep 30, 2024 | AMLX Amylyx Pharmaceuticals, Inc. | Sale(S) | 11,442 | $3.20 | $36,559 | Direct |
1-18 of 18 transactions
About Bedrosian Camille L
Bedrosian Camille L (SEC CIK 0001326969) files insider reports with the SEC as Chief Medical Officer of Amylyx Pharmaceuticals, Inc. (AMLX), Director of Crinetics Pharmaceuticals, Inc. (CRNX) and Director of RHYTHM PHARMACEUTICALS, INC. (RYTM).
Signal8 holds 15 ownership filings by Bedrosian Camille L, all Form 4s, filed between Oct 2, 2024 and Sep 14, 2026. Those filings report 18 transactions, from Sep 30, 2024 to Sep 10, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Bedrosian Camille L's filings is in SAN DIEGO, CA.
Recent filings by Bedrosian Camille L
- Sep 10, 2026: Open-market sales of AMLX shares (2 lines, Form 4, code S).
- Sep 1, 2026: Disposition to issuer transactions of CRNX shares (2 lines, Form 4, code D).
- Aug 18, 2026: Grant or award of AMLX shares (Form 4, code A).
- Jun 18, 2026: Grant or award of CRNX shares (Form 4, code A).
- Mar 5, 2026: Grant or award of AMLX shares (Form 4, code A).
Other insiders filing for Amylyx Pharmaceuticals, Inc. (AMLX)
- MILNE GEORGE M JR, Director
- FRATES JAMES M, Chief Financial Officer
- Mazzariello Gina, Chief Legal Officer
- Klee Justin B., Co-Chief Executive Officer
- Cohen Joshua B, Co-Chief Executive Officer
- Firestone Karen, Director